Oligonucleotide Therapeutics

Oligonucleotide therapeutics are chemical synthesized drugs the main skeleton of which is a chemically modified nucleotide.
Representative examples include antisense oligonucleotide (ASO), RNAi, aptamers and decoys.
Whereas oligonucleotide therapeutics act directly on mRNA, conventional gene therapies deliver a specific DNA gene sequence into the body to express mRNA and produce a protein having a particular function.
Oligonucleotide therapeutics have high specificity and can target specific molecules in cells, which is difficult with existing drugs such as mRNA or non-coding RNA molecules.
Moreover, it is easy to generate candidate agents within a short period because it is a product created by chemical synthesis.
Thus, the development of oligonucleotide therapeutics is advancing and will come into practical use as a next generation pharmaceutical.

Oligonucleotide Therapeutics

・By suppressing the cause of diseases upstream, a smaller amount will be effective.
・Oligonucleotide therapeutics can treat diseases dependent on “alignment” such as diseases caused by genetic mutations. Only oligonucleotide therapeutics can achieve this.

Oligonucleotide Therapeutics

We are expanding our business in the ASO therapeutics area since our modification technologies are suitable for ASO.